Company Directory - GlaxoSmithKline plc
Company Details - GlaxoSmithKline plc

GlaxoSmithKline plc
WebsiteBrentford, United Kingdom
ISIN: GB0009252882
GlaxoSmithKline plc (GSK) is a global healthcare company that researches and develops a broad range of innovative pharmaceutical medicines and consumer healthcare products.
CCI Score
CCI Score: GlaxoSmithKline plc
18.03
-0.01%
Latest Event
GSK Reaffirms Its Non-Political Donations Policy Ahead of 2025 AGM
In its 2025 Annual General Meeting notice, GlaxoSmithKline reiterated its long-standing global policy—implemented from 1 January 2009—not to make political donations. The document also seeks shareholder approval for a limited, capped authority (up to £100,000) for political expenditures, framed strictly as a precautionary measure to comply with regulatory requirements, with no indication that such funds will be used to influence political outcomes.
Take Action
So what can you do? Support GSK by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
SABOTEUR
GlaxoSmithKline plc is currently rated as a Saboteur.
Latest Events
- MAY072025
In its 2025 Annual General Meeting notice, GlaxoSmithKline reiterated its long-standing global policy—implemented from 1 January 2009—not to make political donations. The document also seeks shareholder approval for a limited, capped authority (up to £100,000) for political expenditures, framed strictly as a precautionary measure to comply with regulatory requirements, with no indication that such funds will be used to influence political outcomes.
+70
Political Contributions and Lobbying Efforts
April 9
GSK’s reaffirmation of its policy to abstain from political donations since 2009 is a positive step that minimizes the risk of corporate complicity in political funding that could support authoritarian agendas. By limiting any potential political expenditure to a strictly controlled and capped amount—which historically has not been utilized—the company demonstrates a commitment to keeping its political influence minimal.
- APR012025
Amid concerns over potential tariffs imposed by the Trump administration, GlaxoSmithKline plc announced plans to expand its manufacturing capacity in the United States. This move is seen as a strategy to reduce reliance on global supply chains and to safeguard domestic operations from international trade disruptions.
- MAR032025
GSK has halted its diversity, equity, and inclusion targets, including abandoning aspirational leadership and supplier diversity programmes, in compliance with US legal pressures stemming from Trump’s executive orders. This move raises concerns over the company's commitment to inclusivity and progressive values.
-50
Public and Political Behavior
April 9
By yielding to pressure from President Trump’s orders and pausing its DEI targets, GSK demonstrates capitulation to authoritarian impulses. This political compliance undermines progressive standards and sends a discouraging signal about the corporation's commitment to fostering an inclusive workplace.
-70
Business Practices and Ethical Responsibility
April 9
The decision to abandon aspirational diversity and inclusion targets compromises GSK's ethical responsibility towards marginalized groups. By scaling back DEI initiatives, the company shifts away from practices that support worker rights and inclusivity, thus aligning more closely with regressive, authoritarian policy influences.
- JAN302025
A majority of GSK employees voted for strike action following what the Unite union described as a 'derisory' pay offer, signaling deep-rooted issues in labor relations and corporate fairness amid soaring profits and inflation.
-80
Labor Relations and Human Rights Practices
March 26
The strike vote by GSK workers exposes significant labor rights issues. Despite the company's massive sales and profits, workers are facing a pay offer that is far below the rate of inflation, a situation described as a 'substantial real terms pay cut' by the union. This reflects a pattern of corporate greed and neglect for fair labor practices, intensifying worker exploitation and contributing to a broader narrative of corporate complicity in oppressive economic structures.
GSK workers vote for strike action over "derisory" pay offer
- JAN012023
GlaxoSmithKline plc announced that it will cease corporate donations to political parties worldwide, a move aimed at enhancing transparency and dispelling accusations of undue political influence, thereby distancing itself from potential complicity in authoritarian practices.
+80
Political Contributions and Lobbying Efforts
March 26
GSK's decision to axe its political funds marks a decisive move towards reducing corporate influence in politics. By ending donations to political parties, the company enhances transparency and addresses long-standing criticisms of engaging in practices that may inadvertently support authoritarian or far‐right agendas. This aligns with anti-fascist principles that urge corporations to distance themselves from funding politically divisive activities.
- JAN012023
GlaxoSmithKline has discontinued its corporate political funds program while continuing to offer administrative support for employee contributions to Political Action Committees. The move comes after reports that, in the US, such PACs received £522,000 in contributions last year, and it is seen as a step toward reducing undue corporate influence in political processes.
+70
Political Contributions and Lobbying Efforts
April 9
By axing its corporate political funds, GSK reduces the channel of direct corporate financial influence on political entities. This decision aligns with anti-authoritarian principles by limiting the consolidation of corporate power in political arenas, even though the company continues to provide support for individual employee contributions.
- JAN012023
GlaxoSmithKline announced it will stop using corporate funds for US political contributions to increase transparency, though it continues to allow individual employee donations and support voluntary political action committees.
+80
Political Contributions and Lobbying Efforts
April 9
By eliminating the use of corporate funds for political donations, GSK is reducing the risk of undue corporate influence in politics and promoting transparency. This move aligns with anti-fascist and progressive aims by mitigating the risks of authoritarian patronage and fostering clearer boundaries between business and political financing.
GSK to stop making political donations - Pharmaceutical industry news ...
- MAY242022
Factory workers at GSK received a wage increase after union intervention highlighted a previously derisory offer. This action demonstrates the company's responsiveness to worker demands and commitment to improving labor conditions.
+70
Labor Relations and Human Rights Practices
March 26
GlaxoSmithKline responded to union criticism by significantly increasing factory workers’ pay. Although the initial offer was seen as derisory, the subsequent adjustment shows a commitment to fair labor relations and human rights. This positive move supports worker empowerment and aligns with anti-fascist principles by resisting exploitative practices.
GSK hikes factory workers pay after union calls out derisory offer
- APR292015
GSK announced it would 'voluntarily stop' its direct political contributions to U.S. elected officials but continues to channel substantial funds through its Political Action Committee, raising concerns about its genuine commitment to reducing political influence and its potential complicity in supporting authoritarian practices.
-30
Political Contributions and Lobbying Efforts
March 26
While GSK has publicly declared an end to its direct political donations, the continuation of political funding via its PAC—which outspends the direct contributions—suggests a strategic maneuver to maintain its political influence covertly. This approach undermines efforts toward transparency and accountability, indirectly supporting a system that can favor authoritarian practices.
- DEC232008
GlaxoSmithKline plc has announced the cessation of its corporate political contributions as part of an effort to increase transparency and avoid the appearance of undue influence in politics. This move is intended to reduce the company's financial support to political entities, historically aligned with far-right and authoritarian candidates, thereby limiting corporate complicity in democratic manipulation.
+70
Public and Political Behavior
March 26
By ending its corporate political contributions, GSK is taking a notable step toward reducing its involvement in political financing that has the potential to support authoritarian tendencies. Although the company continues to allow political engagement through an independent Political Action Committee, ceasing direct corporate donations increases transparency and diminishes the risk of financial influence over policy debates. This move is seen as progressive from an anti-fascist perspective as it weakens corporate channels that can bolster far-right ideologies.
- DEC232008
GlaxoSmithKline plc announced it would cease corporate political contributions as part of a transparency push, aiming to eliminate any perception of undue influence in political processes while still supporting an independent Political Action Committee in the US.
+70
Public and Political Behavior
March 26
GSK's decision to end direct corporate political contributions represents a positive move toward reducing undue corporate influence in the political arena, aligning with anti-fascist and transparency priorities. Although the company maintains support for an independent Political Action Committee, which may allow for indirect political influence, the overall action improves separation between corporate financing and political power.
- DEC232008
GlaxoSmithKline announced a new global policy to stop all corporate political contributions, aiming to enhance transparency in its political engagements and avoid the perception of special privileges, while continuing to support a voluntary and independent employee PAC in the US.
+70
Political Contributions and Lobbying Efforts
April 9
By voluntarily ceasing corporate political contributions, GSK reduces the risk of corporate influence over political processes that could favor authoritarian practices. This move enhances transparency and aligns with anti-fascist values by ensuring that political engagement remains free from undue corporate favoritism.
GlaxoSmithKline to cease providing corporate political contributions
- DEC222008
GlaxoSmithKline announced a global ban on corporate political contributions, effective in the United States, Canada, and over 100 countries where it operates, as part of a companywide move towards greater transparency and to eliminate any notion of special privileges. This policy shift marks a departure from previous contributions, with reported donations of $585,425 to U.S. candidates this year and CA$ 58,000 to Canadian politicians in 2007.
+80
Political Contributions and Lobbying Efforts
April 9
By instituting a global ban on corporate political contributions, GSK is reducing its potential to exert undue political influence and promoting transparency in its dealings with governments and political candidates. This shift serves as an anti-fascist measure by distancing the company from practices that can enable authoritarian favoritism.
Alternatives

Darmstadt, Germany
12.29

Dublin, Ireland
-16.04

North Chicago, United States
-31.53

Corporation
27.93
Corporation
-4.89

Cambridge, United Kingdom
-26.64
New York, United States
30.41

Thousand Oaks, USA
13.63

Foster City, USA
1.64

Paris, France
0.42
Corporate Financials
- Revenue
- 2023
- $42.00B
- Total Assets
- 2023
- $51.70B
- Operating Income
- 2023
- $11.50B
- Total Equity
- 2023
- $30.00B
Employees: 99,000
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 325413
- In-Vitro Diagnostic Substance Manufacturing
- 325414
- Biological Product (except Diagnostic) Manufacturing
- 423450
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- 424210
- Drugs and Druggists' Sundries Merchant Wholesalers